Do analysts recommend POLB or BTG?

BTG has a consensus price target of GBX 160, indicating a potential upside of 46.79%. Given BTG's stronger consensus rating and higher probable upside, analysts plainly believe BTG is more favorable than Poolbeg Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Poolbeg Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 BTG 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has stronger earnings and valuation, POLB or BTG?

BTG has higher revenue and earnings than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Poolbeg Pharma N/A N/A -£4.50B -£0.94 N/A BTG £159.40M 1.10 N/A £6.00 18.17

Is POLB or BTG more profitable?

BTG's return on equity of 0.00% beat Poolbeg Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Poolbeg Pharma N/A -55.47% -21.33% BTG N/A N/A N/A

Does the media prefer POLB or BTG?

In the previous week, BTG had 2 more articles in the media than Poolbeg Pharma. MarketBeat recorded 6 mentions for BTG and 4 mentions for Poolbeg Pharma. Poolbeg Pharma's average media sentiment score of -0.17 beat BTG's score of -0.19 indicating that Poolbeg Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Poolbeg Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral BTG 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SCLP or POLB more profitable?

Poolbeg Pharma has a net margin of 0.00% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat Poolbeg Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Scancell -116.98% 90.29% -45.28% Poolbeg Pharma N/A -55.47% -21.33%

Does the media prefer SCLP or POLB?

In the previous week, Poolbeg Pharma had 3 more articles in the media than Scancell. MarketBeat recorded 4 mentions for Poolbeg Pharma and 1 mentions for Scancell. Scancell's average media sentiment score of 0.00 beat Poolbeg Pharma's score of -0.17 indicating that Scancell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scancell 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Poolbeg Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CIR or POLB more profitable?

Circassia Group's return on equity of 0.00% beat Poolbeg Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Circassia Group N/A N/A N/A Poolbeg Pharma N/A -55.47% -21.33%

Is POLB or TILS more profitable?

Tiziana Life Sciences' return on equity of 0.00% beat Poolbeg Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Poolbeg Pharma N/A -55.47% -21.33% Tiziana Life Sciences N/A N/A N/A

Poolbeg Pharma (POLB) Competitors

GBX 6.18 +0.03 (+0.50%)

As of 12:34 PM Eastern

Compare

POLB vs. ARIX, BTG, SCLP, CIR, and TILS

Should you buy Poolbeg Pharma stock or one of its competitors? MarketBeat compares Poolbeg Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Poolbeg Pharma include Arix Bioscience (ARIX), BTG (BTG), Scancell (SCLP), Circassia Group (CIR), and Tiziana Life Sciences (TILS). These companies are all part of the "biotechnology" industry.

How does Poolbeg Pharma compare to Arix Bioscience?

Arix Bioscience (LON:ARIX) and Poolbeg Pharma (LON:POLB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

In the previous week, Poolbeg Pharma had 4 more articles in the media than Arix Bioscience. MarketBeat recorded 4 mentions for Poolbeg Pharma and 0 mentions for Arix Bioscience. Arix Bioscience's average media sentiment score of 0.00 beat Poolbeg Pharma's score of -0.17 indicating that Arix Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Arix Bioscience	Neutral
Poolbeg Pharma	Neutral

Arix Bioscience has higher revenue and earnings than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arix Bioscience	£14.16M	0.00	£14.96M	£0.11	N/A
Poolbeg Pharma	N/A	N/A	-£4.50B	-£0.94	N/A

Arix Bioscience has a net margin of 105.64% compared to Poolbeg Pharma's net margin of 0.00%. Arix Bioscience's return on equity of 6.41% beat Poolbeg Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arix Bioscience	105.64%	6.41%	2.18%
Poolbeg Pharma	N/A	-55.47%	-21.33%

41.3% of Arix Bioscience shares are owned by institutional investors. Comparatively, 1.5% of Poolbeg Pharma shares are owned by institutional investors. 20.7% of Arix Bioscience shares are owned by insiders. Comparatively, 7.5% of Poolbeg Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Arix Bioscience has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market. Comparatively, Poolbeg Pharma has a beta of 1.812, suggesting that its share price is 81% more volatile than the broader market.

Summary

Arix Bioscience beats Poolbeg Pharma on 10 of the 12 factors compared between the two stocks.

How does Poolbeg Pharma compare to BTG?

Poolbeg Pharma (LON:POLB) and BTG (LON:BTG) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

In the previous week, BTG had 2 more articles in the media than Poolbeg Pharma. MarketBeat recorded 6 mentions for BTG and 4 mentions for Poolbeg Pharma. Poolbeg Pharma's average media sentiment score of -0.17 beat BTG's score of -0.19 indicating that Poolbeg Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Poolbeg Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
BTG	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

BTG has higher revenue and earnings than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Poolbeg Pharma	N/A	N/A	-£4.50B	-£0.94	N/A
BTG	£159.40M	1.10	N/A	£6.00	18.17

BTG has a consensus price target of GBX 160, indicating a potential upside of 46.79%. Given BTG's stronger consensus rating and higher probable upside, analysts plainly believe BTG is more favorable than Poolbeg Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Poolbeg Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
BTG	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

BTG's return on equity of 0.00% beat Poolbeg Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Poolbeg Pharma	N/A	-55.47%	-21.33%
BTG	N/A	N/A	N/A

1.5% of Poolbeg Pharma shares are held by institutional investors. Comparatively, 19.2% of BTG shares are held by institutional investors. 7.5% of Poolbeg Pharma shares are held by company insiders. Comparatively, 19.7% of BTG shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

BTG beats Poolbeg Pharma on 11 of the 12 factors compared between the two stocks.

How does Poolbeg Pharma compare to Scancell?

Scancell (LON:SCLP) and Poolbeg Pharma (LON:POLB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

1.5% of Scancell shares are owned by institutional investors. Comparatively, 1.5% of Poolbeg Pharma shares are owned by institutional investors. 15.5% of Scancell shares are owned by company insiders. Comparatively, 7.5% of Poolbeg Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Poolbeg Pharma had 3 more articles in the media than Scancell. MarketBeat recorded 4 mentions for Poolbeg Pharma and 1 mentions for Scancell. Scancell's average media sentiment score of 0.00 beat Poolbeg Pharma's score of -0.17 indicating that Scancell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scancell	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Poolbeg Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Scancell has a beta of 0.736, suggesting that its share price is 26% less volatile than the broader market. Comparatively, Poolbeg Pharma has a beta of 1.812, suggesting that its share price is 81% more volatile than the broader market.

Scancell has higher revenue and earnings than Poolbeg Pharma. Scancell is trading at a lower price-to-earnings ratio than Poolbeg Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scancell	£4.71M	29.19	-£6.75M	-£0.55	N/A
Poolbeg Pharma	N/A	N/A	-£4.50B	-£0.94	N/A

Poolbeg Pharma has a net margin of 0.00% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat Poolbeg Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scancell	-116.98%	90.29%	-45.28%
Poolbeg Pharma	N/A	-55.47%	-21.33%

Summary

Scancell and Poolbeg Pharma tied by winning 6 of the 12 factors compared between the two stocks.

How does Poolbeg Pharma compare to Circassia Group?

Circassia Group (LON:CIR) and Poolbeg Pharma (LON:POLB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

Circassia Group's return on equity of 0.00% beat Poolbeg Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Circassia Group	N/A	N/A	N/A
Poolbeg Pharma	N/A	-55.47%	-21.33%

1.5% of Poolbeg Pharma shares are owned by institutional investors. 7.5% of Poolbeg Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Circassia Group has higher revenue and earnings than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Circassia Group	£27.90M	0.00	N/A	£0.01	N/A
Poolbeg Pharma	N/A	N/A	-£4.50B	-£0.94	N/A

In the previous week, Poolbeg Pharma had 4 more articles in the media than Circassia Group. MarketBeat recorded 4 mentions for Poolbeg Pharma and 0 mentions for Circassia Group. Circassia Group's average media sentiment score of 0.00 beat Poolbeg Pharma's score of -0.17 indicating that Circassia Group is being referred to more favorably in the media.

Company	Overall Sentiment
Circassia Group	Neutral
Poolbeg Pharma	Neutral

Summary

Circassia Group beats Poolbeg Pharma on 6 of the 9 factors compared between the two stocks.

How does Poolbeg Pharma compare to Tiziana Life Sciences?

Poolbeg Pharma (LON:POLB) and Tiziana Life Sciences (LON:TILS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

1.5% of Poolbeg Pharma shares are held by institutional investors. 7.5% of Poolbeg Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Tiziana Life Sciences has lower revenue, but higher earnings than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Poolbeg Pharma	N/A	N/A	-£4.50B	-£0.94	N/A
Tiziana Life Sciences	-£3.60M	0.00	N/A	-£16.30	N/A

Tiziana Life Sciences' return on equity of 0.00% beat Poolbeg Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Poolbeg Pharma	N/A	-55.47%	-21.33%
Tiziana Life Sciences	N/A	N/A	N/A

In the previous week, Poolbeg Pharma had 4 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 4 mentions for Poolbeg Pharma and 0 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 0.00 beat Poolbeg Pharma's score of -0.17 indicating that Tiziana Life Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Poolbeg Pharma	Neutral
Tiziana Life Sciences	Neutral

Summary

Poolbeg Pharma beats Tiziana Life Sciences on 5 of the 9 factors compared between the two stocks.

Get Poolbeg Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding POLB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

POLB vs. The Competition

Export

Metric	Poolbeg Pharma	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£43.58M	£517.36M	£6.89B	£2.77B
Dividend Yield	N/A	3.90%	2.67%	6.15%
P/E Ratio	-6.58	3.48	27.17	368.16
Price / Sales	N/A	6,483.71	526.21	84,554.80
Price / Cash	2.11	13.13	51.46	27.89
Price / Book	0.00	87.30	10.69	7.53
Net Income	-£4.50B	-£96.07M	£3.59B	£5.89B
7 Day Performance	-11.70%	-2.28%	-2.17%	5.85%
1 Month Performance	-20.12%	1.15%	2.08%	4.48%
1 Year Performance	106.03%	58.09%	24.68%	62.28%

Poolbeg Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
POLB Poolbeg Pharma	N/A	GBX 6.18 +0.5%	N/A	+96.5%	£43.58M	N/A	N/A	12	High Trading Volume
ARIX Arix Bioscience	N/A	N/A	N/A	N/A	£183.73M	£14.16M	1,290.91	9
BTG BTG	4.3463 of 5 stars	GBX 112 +3.7%	GBX 160 +42.9%	N/A	£180.48M	£159.40M	18.67	4,690	Gap Up High Trading Volume
SCLP Scancell	N/A	GBX 14.85 +0.7%	N/A	+37.8%	£154.11M	£4.71M	N/A	51	News Coverage
CIR Circassia Group	N/A	N/A	N/A	N/A	£142.66M	£27.90M	3,400.00	111	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:POLB) was last updated on 7/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Poolbeg Pharma (POLB) Competitors

POLB vs. ARIX, BTG, SCLP, CIR, and TILS

How does Poolbeg Pharma compare to Arix Bioscience?

Summary

How does Poolbeg Pharma compare to BTG?

Summary

How does Poolbeg Pharma compare to Scancell?

Summary

How does Poolbeg Pharma compare to Circassia Group?

Summary

How does Poolbeg Pharma compare to Tiziana Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

POLB vs. The Competition

Poolbeg Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Poolbeg Pharma (POLB) Competitors

POLB vs. ARIX, BTG, SCLP, CIR, and TILS

How does Poolbeg Pharma compare to Arix Bioscience?

Does the media prefer ARIX or POLB?

Which has stronger valuation and earnings, ARIX or POLB?

Is ARIX or POLB more profitable?

Do institutionals & insiders have more ownership in ARIX or POLB?

Which has more volatility & risk, ARIX or POLB?

Summary

How does Poolbeg Pharma compare to BTG?

Does the media prefer POLB or BTG?

Which has stronger earnings and valuation, POLB or BTG?

Do analysts recommend POLB or BTG?

Is POLB or BTG more profitable?

Do institutionals & insiders believe in POLB or BTG?

Summary

How does Poolbeg Pharma compare to Scancell?

Do institutionals & insiders hold more shares of SCLP or POLB?

Does the media prefer SCLP or POLB?

Which has more risk & volatility, SCLP or POLB?

Which has better earnings & valuation, SCLP or POLB?

Is SCLP or POLB more profitable?

Summary

How does Poolbeg Pharma compare to Circassia Group?

Is CIR or POLB more profitable?

Do institutionals and insiders have more ownership in CIR or POLB?

Which has higher valuation and earnings, CIR or POLB?

Does the media prefer CIR or POLB?

Summary

How does Poolbeg Pharma compare to Tiziana Life Sciences?

Do insiders & institutionals hold more shares of POLB or TILS?

Which has preferable valuation & earnings, POLB or TILS?

Is POLB or TILS more profitable?

Does the media refer more to POLB or TILS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

POLB vs. The Competition

Poolbeg Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools